Stifel raised the firm’s price target on Artivion (AORT) to $46 from $40 and keeps a Buy rating on the shares. After having checked in with five cardiac surgeons about their latest On-X utilization trends, the firm tells investors that the physicians offered “constructive comments” and said that the broader cardiac surgeon community could be reacting incrementally more positively to the data in a January 2025 JACC medical-journal paper.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT: